Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats

Basic and Clinical Pharmacology and Toxicology

Volumn 102, Issue 5, 2008, Pages 453-458

  Ghosh, Sarbani ^a   Chiang, Po Chang ^a   Wahlstrom, Jan L ^a   Fujiwara, Hideji ^a   Selbo, Jon G ^a   Roberds, Steven L ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DICYCLOHEXYLUREA; ANGIOTENSIN II; EPOXIDE HYDROLASE; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EXPOSURE; DRUG FORMULATION; DRUG INFUSION; DRUG MECHANISM; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; MALE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SUSPENSION; TREATMENT DURATION;

8,11,14-EICOSATRIENOIC ACID; ADMINISTRATION, ORAL; ANIMALS; BLOOD PRESSURE; CHROMATOGRAPHY, LIQUID; DISEASE MODELS, ANIMAL; EPOXIDE HYDROLASES; HYPERTENSION; MALE; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SUSPENSIONS; TANDEM MASS SPECTROMETRY; UREA;

RATTUS;

EID: 42149190687     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2008.00213.x     Document Type: Article

References (40)

1. Zhao X, Imig JD. Kidney CYP450 enzymes: biological actions beyond drug metabolism. Curr Drug Metab 2003 4 : 73 84.
2. Node K, Huo Y, Ruan X et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999 285 : 1276 9.
3. Fang X, Moore SA, Stoll LL et al. 14,15-Epoxyeicosatrienoic acid inhibits prostaglandin E2 production in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 1998 275 : H2113 21.
4. Schmelzer KR, Inceoglu B, Kubala L et al. Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci USA 2006 103 : 13646 51.
5. Smith KR, Pinkerton KE, Watanabe T, Pedersen TL, Ma SJ, Hammock BD. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc Natl Acad Sci USA 2005 102 : 2186 91.
6. Capdevila JH, Falck JR. The CYP P450 Arachidonic acid monooxygenases: from cell signaling to blood pressure regulation. Biochem Biophys Res Commun 2001 285 : 571 6.
7. Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 2001 276 : 36059 62.
8. Makita K, Takahashi K, Karara A, Jacobson HR, Falck JR, Capdevila JH. Experimental and/or genetically controlled alterations of the renal microsomal cytochrome P450 epoxygenase induced hypertension in rats fed a high salt diet. J Clin Invest 1994 94 : 2414 20.
9. Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 1996 78 : 415 23.
10. Fisslthaler B, Popp R, Kiss L et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 1999 401 : 493 7.
11. Imig JD, Falck JR, Wei S, Capdevila JH. Epoxygenase metabolites contribute to nitric oxide-independent afferent arteriolar vasodilation in response to bradykinin. J Vasc Res 2001 38 : 247 55.
12. Imig JD. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol 2005 289 : F496 503.
13. Katoh T, Takahashi K, Capdevila J et al. Glomerular stereospecific synthesis and hemodynamic actions of 8,9-epoxyeicosatrienoic acid in rat kidney. Am J Physiol Renal Physiol 1991 261 : F578 86.
14. Lin W-K, Falck JR, Wong PY-K. Effect of 14,15-epoxyeicosatrienoic acid infusion on blood pressure in normal and hypertensive rats. Biochem Biophys Res Commun 1990 167 : 977 81.
15. Imig JD, Navar LG, Roman RJ, Reddy KK, Falck JR. Actions of epoxygenase metabolites on the preglomerular vasculature. J Am Soc Nephrol 1996 7 : 2364 70.
16. Gauthier KM, Edwards EM, Falck JR, Reddy DS, Campbell WB. 14,15-Epoxyeicosatrienoic acid represents a transferable endothelium-dependent relaxing factor in bovine coronary arteries. Hypertension 2005 45 : 666 71.
17. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002 82 : 131 85.
18. Wong PY-K, Lai P-S, Shen S-Y, Belosludtsev YY, Falck JR. Post-receptor signal transduction and regulation of 14(R),15(S)-epoxyeicosatrienoic acid (14,15-EET) binding in U-937 cells. J Lipid Mediat Cell Signal 1997 16 : 155 69.
19. Carroll MA, Doumad AB, Li J, Cheng, MK, Falck JR, McGiff JC. Adenosine2A receptor vasodilation of rat preglomerular microvessels is mediated by EETs that activate the cAMP/PKA pathway. Am J Physiol Renal Physiol 2006 291 : F155 61.
20. Zhao X, Dey A, Romanko OP et al. Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 2005 288 : R188 96.
21. Spector AA, Fang X, Snyder GD, Weintraub NL. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res 2004 43 : 55 90.
22. Yu Z, Xu F, Huse LM et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 2000 87 : 992 8.
23. Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 2002 39 : 690 4.
24. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, Gonzalez FJ. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 2000 275 : 40504 10.
25. Zhao X, Yamamoto T, Newman JW et al. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol 2004 15 : 1244 53.
26. + channels and p42/p44 MAPK pathway. Circ Res 2004 95 : 506 14.
27. Gross GJ, Falck JR, Gross ER, Isbell M, Moore J, Nithipatikom K. Role in myocardial ischemia/reperfusion injury revisited. Cardiovasc Res 2005 68 : 18 25.
28. Wang M-H. Renal cytochrome P450-derived eicosanoids and hypertension. Current Hypertension Reviews 2006 2 : 227 36.
29. Kaergel E, Muller DN, Honeck H et al. P450-dependent arachidonic acid metabolism and angiotensin II-induced renal damage. Hypertension 2002 40 : 273 9.
30. Olearczyk JJ, Imig JD. Epoxyeicosatrienoic acids as a therapeutic target for nephropathy associated with diabetes and hypertension. Current Hypertension Reviews 2005 1 : 235 42.
31. Brazeau GA, Fung HL. Mechanisms of creatine kinase release from isolated rat skeletal muscles damaged by propylene glycol and ethanol. J Pharm Sci 1990 79 : 393 7.
32. Korttila K, Sothman A, Andersson P. Polyethylene glycol as a solvent for diazepam: bioavailability and clinical effects after intramuscular administration, comparison of oral, intramuscular and rectal administration, and precipitation from intravenous solutions. Acta Pharmacol Toxicol (Copenh) 1976 39 : 104 17.
33. Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov 2004 3 : 785 96.
34. Liversidge GG, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm 1995 125 : 91 7.
35. Haskell RJ. Laboratory Scale Milling Process. 2004 United State Patent, Patent No. US 6814319 B2
36. Martin, A. Physical Pharmay, 4th edn. Williams & Wilkins, Baltimore, MD, 1993.
37. Budden R, Kuhl UG, Bahlsen J. Experiments on toxic, sedative and muscle relaxant potency of various drug solvents in mice. Pharmacol Ther 1979 5 : 467 74.
38. Pestel S, Martin H-J, Maier G-M, Guth B. Effect of commonly used vehicles on gastrointestinal, renal, and liver function in rats. J Pharmacol Toxicol Methods 2006 54 : 200 14.
39. Chiang P-C, Wahlstrom JL, Selbo JG et al. 1,3-Dicyclohexyl urea nanosuspendion for intravenous steady-state delivery in rats. J Exp Nanosci 2007 2 : 239 50.
40. Wahlstrom JL, Chiang PC, Ghosh S et al. Pharmacokinetic evaluation of a 1,3-dicyclohexylurea nanosuspension formulation to support early efficacy assessment. Nanoscale Res Lett 2007 2 : 291 6.